Janux Therapeutics (JANX)
(Delayed Data from NSDQ)
$49.99 USD
+1.07 (2.19%)
Updated May 13, 2024 04:00 PM ET
After-Market: $49.95 -0.04 (-0.08%) 6:28 PM ET
3-Hold of 5 3
F Value F Growth A Momentum F VGM
Balance Sheet
Fiscal Year End for Janux Therapeutics, Inc falls in the month of December.
All items in Millions except Per Share data.
12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 | |
---|---|---|---|---|---|
Assets | |||||
Cash & Equivalents | 344 | 327 | 375 | 8 | 1 |
Receivables | 0 | 0 | 0 | 8 | 0 |
Notes Receivable | 0 | 0 | 0 | 0 | 0 |
Inventories | 0 | 0 | 0 | 0 | 0 |
Other Current Assets | 5 | 5 | 2 | 0 | 0 |
Total Current Assets | 349 | 332 | 377 | 16 | 1 |
Net Property & Equipment | 7 | 7 | 1 | 0 | 0 |
Investments & Advances | 0 | 0 | 0 | 0 | 0 |
Other Non-Current Assets | 0 | 0 | 0 | 0 | 0 |
Deferred Charges | 0 | 0 | 0 | 0 | 0 |
Intangibles | 0 | 0 | 0 | 0 | 0 |
Deposits & Other Assets | 3 | 2 | 1 | 0 | 0 |
Total Assets | 380 | 364 | 380 | 16 | 1 |
Liabilities & Shareholders Equity | 12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 |
---|---|---|---|---|---|
Notes Payable | 0 | 0 | 0 | 0 | 4 |
Accounts Payable | 2 | 2 | 2 | 0 | 0 |
Current Portion Long-Term Debt | 0 | 0 | 0 | 0 | 0 |
Current Portion Capital Leases | 0 | 0 | 0 | 0 | 0 |
Accrued Expenses | 7 | 8 | 4 | 1 | 0 |
Income Taxes Payable | 0 | 0 | 0 | 0 | 0 |
Other Current Liabilities | 2 | 6 | 6 | 2 | 0 |
Total Current Liabilities | 13 | 17 | 13 | 3 | 5 |
Mortgages | 0 | 0 | 0 | 0 | 0 |
Deferred Taxes/Income | 0 | 2 | 1 | 6 | 0 |
Convertible Debt | 0 | 0 | 0 | 0 | 0 |
Long-Term Debt | 0 | 0 | 0 | 0 | 0 |
Non-Current Capital Leases | 0 | 0 | 0 | 0 | 0 |
Other Non-Current Liabilities | 0 | 0 | 0 | 0 | 0 |
Minority Interest (Liabilities) | 0 | 0 | 0 | 0 | 0 |
Total Liabilities | 36 | 43 | 14 | 9 | 5 |
Shareholders Equity | 12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 |
---|---|---|---|---|---|
Preferred Stock | 0 | 0 | 0 | 22 | 4 |
Common Stock (Par) | 0 | 0 | 0 | 0 | 0 |
Capital Surplus | 512 | 433 | 414 | 0 | 0 |
Retained Earnings | -169 | -110 | -47 | -15 | -8 |
Other Equity | 1 | -2 | 0 | 0 | 0 |
Treasury Stock | 0 | 0 | 0 | 0 | 0 |
Total Shareholder's Equity | 344 | 321 | 366 | 7 | -4 |
Total Liabilities & Shareholder's Equity | 380 | 364 | 380 | 16 | 1 |
Total Common Equity | 344 | 321 | 366 | -15 | -8 |
Shares Outstanding | 46.10 | 41.60 | 41.60 | NA | NA |
Book Value Per Share | 7.47 | 7.71 | 8.81 | 0.00 | 0.00 |
Fiscal Year End for Janux Therapeutics, Inc falls in the month of December.
All items in Millions except Per Share data.
3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 | 3/31/2023 | |
---|---|---|---|---|---|
Assets | |||||
Cash & Equivalents | 652 | 344 | 350 | 303 | 317 |
Receivables | 1 | 0 | 0 | 0 | 1 |
Notes Receivable | 0 | 0 | 0 | 0 | 0 |
Inventories | 0 | 0 | 0 | 0 | 0 |
Other Current Assets | 6 | 5 | 5 | 6 | 4 |
Total Current Assets | 659 | 349 | 355 | 309 | 321 |
Net Property & Equipment | 7 | 7 | 7 | 7 | 7 |
Investments & Advances | 0 | 0 | 0 | 0 | 0 |
Other Non-Current Assets | 0 | 0 | 0 | 0 | 0 |
Deferred Charges | 0 | 0 | 0 | 0 | 0 |
Intangibles | 0 | 0 | 0 | 0 | 0 |
Deposits & Other Assets | 3 | 3 | 3 | 3 | 2 |
Total Assets | 689 | 380 | 387 | 342 | 353 |
Liabilities & Shareholders Equity | 3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 | 3/31/2023 |
---|---|---|---|---|---|
Notes Payable | 0 | 0 | 0 | 0 | 0 |
Accounts Payable | 2 | 2 | 3 | 2 | 2 |
Current Portion Long-Term Debt | 0 | 0 | 0 | 0 | 0 |
Current Portion Capital Leases | 0 | 0 | 0 | 0 | 0 |
Accrued Expenses | 6 | 7 | 7 | 9 | 8 |
Income Taxes Payable | 0 | 0 | 0 | 0 | 0 |
Other Current Liabilities | 1 | 2 | 4 | 5 | 5 |
Total Current Liabilities | 11 | 13 | 14 | 18 | 16 |
Mortgages | 0 | 0 | 0 | 0 | 0 |
Deferred Taxes/Income | 0 | 0 | 0 | 0 | 1 |
Convertible Debt | 0 | 0 | 0 | 0 | 0 |
Long-Term Debt | 0 | 0 | 0 | 0 | 0 |
Non-Current Capital Leases | 0 | 0 | 0 | 0 | 0 |
Other Non-Current Liabilities | 0 | 0 | 0 | 0 | |
Minority Interest (Liabilities) | 0 | 0 | 0 | 0 | 0 |
Total Liabilities | 33 | 36 | 38 | 42 | 42 |
Shareholders Equity | 3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 | 3/31/2023 |
---|---|---|---|---|---|
Preferred Stock | 0 | 0 | 0 | 0 | 0 |
Common Stock (Par) | 0 | 0 | 0 | 0 | 0 |
Capital Surplus | 840 | 512 | 507 | 446 | 440 |
Retained Earnings | -184 | -169 | -157 | -145 | -128 |
Other Equity | -1 | 1 | -1 | -1 | -1 |
Treasury Stock | 0 | 0 | 0 | 0 | 0 |
Total Shareholder's Equity | 656 | 344 | 349 | 299 | 311 |
Total Liabilities & Shareholder's Equity | 689 | 380 | 387 | 342 | 353 |
Total Common Equity | 656 | 344 | 349 | 299 | 311 |
Shares Outstanding | 51.80 | 46.10 | 46.10 | 41.80 | 41.80 |
Book Value Per Share | 12.66 | 7.47 | 7.57 | 7.16 | 7.45 |